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 ABSTRACT 
The tumor suppressor p53, encoded by TP53, is known as the ’guardian of the genome’. 
Sulfotransferases (SULTs) are involved in the metabolism of alkylated polycyclic aromatic 
hydrocarbons such 1-hydroxymethylpyrene (1-HMP) which is a known substrate for 
SULT1A1. To investigate the impact of TP53 on the metabolic activation of 1-HMP a panel 
of isogenic human colorectal HCT116 cells having TP53(+/+), TP53(+/-) or TP53(-/-) were 
treated with 10 μM 1-HMP for 24 hours. 1-HMP-DNA adduct formation was determined by 
ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) 
analysis, which quantified two nucleoside adducts N2-(1-methylpyrenyl)-2’-deoxyguanosine 
(MPdG) and N6-(1-methylpyrenyl)-2’-deoxyadenosine (MPdA). 1-HMP treatment resulted in 
significantly (~40-fold) higher DNA adduct levels in TP53(+/+) cells than in the other cell 
lines. Higher levels of 1-HMP-induced DNA adducts in TP53(+/+) cells correlated with higher 
basal expression of SULT1A1/3 in this cell line but 1-HMP treatment showed no effect on the 
expression of this protein. These results indicate that the cellular TP53 status is linked to the 
SULT1A1/3-mediated bioactivation of 1-HMP thereby broadening the spectrum of p53’s 
targets.  
 
Key words: tumor suppressor p53, carcinogen activation, sulfotransferase, DNA adduct, 
alkylated polycyclic aromatic hydrocarbons 
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 INTRODUCTION 
Like unsubstituted polycyclic aromatic hydrocarbons (PAHs), alkylated PAHs are also 
formed through incomplete combustion of organic matter, although preferentially at lower 
combustion temperatures (Flesher and Lehner 2016). They can also be generated as a result of 
diagenic processes of organic sediments (e.g. mineral oil and coal) (Richter-Brockmann and 
Achten 2018). 1-Methylpyrene (1-MP), one such alkylated PAH, is a widespread 
environmental pollutant detectable in various foods (native olive oil, smoked cheese, cooking 
margarine, coffee brew, and grilled sausages) and it bioaccumulates in marine creatures such 
as mussels, crabs and finfish (Bendadani et al. 2014a; Bendadani et al. 2014b). It can also be 
found in car exhausts and is present in cigarette smoke condensate at higher concentrations 
than the reference PAH, benzo[a]pyrene (BaP) (Bakhiya et al. 2006). 1-MP is 
hepatocarcinogenic in rodents (Rice et al. 1987) but to date insufficient data are available on 
the carcinogenic risk to humans. Alkylated PAHs like 1-MP require metabolic activation into 
electrophilic intermediates to exert their genotoxic effects (Flesher and Lehner 2016). CYP-
catalyzed biotransformation of 1-MP yields 1-hydroxymethylpyrene (1-HMP), which is further 
activated by sulfotransferases (SULTs), particularly SULT1A1, to 1-sulfoxymethylpyrene (1-
SMP) (Figure 1) (Bendadani et al. 2014a). 1-SMP forms DNA adducts in vitro and in vivo, 
with N2-(1-methylpyrenyl-2’-deoxyguanosine (MPdG) and N6-(1-methylpyrenyl)-2’-
deoxyadenosine (MPdA) identified as major adducts (Monien et al. 2008). 1-SMP has been 
shown to induce tumors in mice and rats (Surh et al. 1990; Horn et al. 1996).   
The tumor suppressor p53, encoded by TP53, is mutated in approximately 50% of 
sporadic tumors making it arguably one of the most important cancer genes (Olivier et al. 
2010). p53 can be induced by multiple forms of cellular stress (e.g. DNA damage) and it 
functions at the crossroads of a network of signaling pathways that are crucial for regulating 
cell growth and apoptosis. Its response to DNA damage is to abrogate DNA synthesis or cell 
division and this has earned p53 the term ‘guardian of the genome’. Disruption of the normal 
p53 response by TP53 mutation leads to the development of tumors and various carcinogens 
have been associated with characteristic mutational signatures (Kucab et al. 2015). In addition 
to the role of p53 in DNA damage response, new functions are still being discovered. Over 
recent years a role for p53 in modulating carcinogen metabolism has emerged (Hockley et al. 
2008; Simoes et al. 2008; Krais et al. 2016a; Krais et al. 2016b; Wohak et al. 2016; Willis et 
al. 2018; Wohak et al. 2018). We have shown that DNA adduct formation by BaP was 
significantly impacted by p53 function both in vitro and in vivo and that the observed DNA 
damage correlates with CYP1A1 expression (Krais et al. 2016a; Wohak et al. 2016). A recent 
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 study of the air pollutant 3-nitrobenzanthrone (3-NBA) and its metabolites 3-
aminobenzanthrone (3-ABA) and N-hydroxy-3-aminobenzanthrone (N-OH-3-ABA) 
illustrated that p53’s influence on carcinogen metabolism depends on the class of carcinogen 
and on the xenobiotic-metabolizing enzymes (XMEs) mediating the bioactivation (Wohak et 
al. 2018). This was also the first study indicating that p53 can impact on SULT-mediated (i.e. 
SULT1A1) carcinogen metabolism (Wohak et al. 2018).     
In the present study we used isogenic human colorectal HCT116 cells differing in their 
TP53 status as model to further investigate the impact of cellular p53 function on SULT-
mediated carcinogen activation. HCT116 TP53(+/+), TP53(+/-), and TP53(-/-) cells were 
compared for their ability to metabolically activate 1-HMP. 1-HMP-DNA adduct formation 
was measured by liquid chromatography-tandem mass spectrometry (LC-MS/MS) and 
SULT1A1/3 expression was determined by Western blotting.  
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 MATERIAL AND METHODS 
 
Carcinogen 
1-HMP (CAS no. 24463-15-9; purity 98%) was purchased from Sigma Aldrich. 
 
Cell culture and treatment 
Human colorectal HCT116 TP53(+/+), TP53(+/-), and TP53(-/-) cells were kindly 
provided by Prof. Bert Vogelstein, Johns Hopkins University School of Medicine, Baltimore, 
MD. Cells were grown as adherent monolayers as described (Wohak et al. 2016; Wohak et al. 
2018). For treatment, cells were seeded at 3  104 cells/cm2, grown for 48 hours and 
subsequently treated for up to 48 hours with 0, 1, 10, or 20 µM 1-HMP dissolved in dimethyl 
sulfoxide (DMSO; 0.5% final volume of medium).  
 
Cell viability 
Cells were seeded on 96-well plates for up to 48 hours. Cell viability after 1-HMP 
treatment was assessed using a crystal violet staining assay as reported (Wohak et al. 2018). 
 
DNA adduct analysis  
Cells were seeded in 75-cm2 flasks and treated with 10 µM 1-HMP for 24 hours. To 
obtain sufficient DNA (~100 µg) for analysis cells were pooled from two flasks prior DNA 
isolation using a standard phenol/chloroform extraction method. 1-HMP-DNA adducts were 
measured by isotope-dilution ultra-performance liquid chromatography-tandem mass 
spectrometry (UPLC-MS/MS) as described elsewhere (Monien et al. 2008). Briefly, DNA (100 
μg) was spiked with isotope-labeled standards (250 fmol [15N5]MPdA and 2.5 pmol 
[15N5,
13C10]MPdG), digested enzymatically to nucleosides, and subjected to solid-phase 
extraction for enrichment of the adducts as reported (Monien et al. 2008; Monien et al. 2009). 
Sample separation was performed using an Acquity ultraperformance liquid chromatography 
(UPLC) system with a BEH Phenyl column (1.7 μm, 2.1 × 100 mm) and analyzed with a 
Quattro Premier XE tandem quadrupole mass spectrometer using an electrospray interface 
operated in the positive ion mode (all from Waters, Eschborn, Germany). For quantification 
(quantifier) the neutral loss of the furanose unit (MPdA 466.3  350.1 and MPdG 482.3  
366.1) was used with [15N5]MPdA (471.3  355.1) and [15N5 13C10]MPdG (497.3  376.1) as 
internal standards, while the fragmentation into nucleoside and the 1-MP cation (m/z = 215.1) 
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 was used to confirm the identity of the substance (qualifier). The tune parameters for MPdA 
were [deviating parameters for MPdG are given in parentheses]: temperature of the 
electrospray source, 110°C; desolvation temperature, 485°C [MPdG 495°C]; desolvation gas, 
nitrogen (850 L/hour); cone gas, nitrogen (50 L/hour); collision gas, argon (indicated cell 
pressure 4.6 × 10-3 mbar). Fragmentation of MPdA required 35 and 18 eV collision energies 
for the transitions 466.3  215.1 and 466.3  350.3, respectively. Collision energies for 
fragmentation of MPdG were 30 and 10 eV for the transitions 482.3  215.1 and 482.3  
366.3, respectively. Further experimental parameters were set as follows: dwell time, 100 ms; 
capillary voltage, 4 kV (MPdG 3.8 kV); cone voltage, 30 (MPdG 25 V); RF1 lens voltage, 0.1 
V. Data acquisition and handling were performed with MassLynx software. The limits of 
detection (LOD) were at approximately 3 MPdG and 0.6 MPdA per 108 nucleosides (Monien 
et al. 2008). All samples were analyzed twice, and results were usually within 15% variation. 
 
Western blot analysis 
Cells were seeded in 25-cm2 flasks and treated with 10 µM 1-HMP for up to 48 hours. 
Western blotting was performed as described (Wohak et al. 2018). Primary antibodies and 
dilutions used were: anti-p53 1:2000 (Ab-6; Calbiochem), anti-p21 (CDKN1A) 1:2000 
(556431; BD Pharmingen) and anti-SULT1A1/3 1:5000. Anti-SULT1A1/3 was a generous gift 
from Prof. Hansruedi Glatt (German Institute of Human Nutrition, Nuthetal, Germany). This 
antiserum was raised in rabbits against bacterial inclusion bodies of human SULT1A (Teubner 
et al. 2007) and was shown to exhibit some cross-reactivity detecting human SULT1A1 and 
SULT1A3. -Actin (1:20000; ab6276, Abcam) was used as loading control. 
 
Statistical analysis 
Statistical analyses were performed with Prism GraphPad Software (Version 7.04) and 
p < 0.05 was considered significant. 
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 RESULTS 
 
Cell viability in HCT116 cells after exposure to 1-HMP 
Firstly, the effect of 1-HMP on the viability of HCT116 cells was evaluated (Figure 2). 
TP53(+/+), TP53(+/-), and TP53(-/-) cells were exposed to 5, 10 and 20 M 1-HMP or DMSO 
alone (control) for 24 and 48 hours. These concentrations were chosen according to previous 
studies (Glatt et al. 1994; Jiang et al. 2015). TP53(+/-) cells showed the strongest sensitivity to 
1-HMP exposure; at 20 M viability was decreased to 77% and 72% after 24 and 48 hours, 
respectively (Figure 2). At the lower concentrations of 5 and 10 M TP53(+/-) cell viability 
was >85%. For TP53(+/+) and TP53(-/-) cells at least 85% stayed viable at all the 
concentrations and time points tested (Figure 2).  
 
DNA adduct formation in HCT116 cells treated with 1-HMP 
Based on some initial tests in HCT116 TP53(+/+) cells (data not shown), 10 M 1-
HMP and a 24-hour incubation time were selected to compare 1-HMP-induced DNA adduct 
formation in TP53(+/+), TP53(+/-) and TP53(-/-) cells. Figure 3B shows representative 
UPLC-MS/MS chromatograms of digested DNA from 1-HMP-treated TP53(+/+) cells. MPdG 
levels were about 15-fold higher than MPdA levels in all cell lines (Figure 3A). This trend 
coincides with previous findings that reported MPdG to be the predominant 1-HMP-DNA 
adduct formed (Bendadani et al. 2014b). Strikingly, levels of both DNA adducts were 
significantly higher in TP53(+/+) cells than in TP53(+/-) and TP53(-/-) cells (Figure 3A) 
(MPdA: ~40-fold compared to TP53(+/-) and TP53(-/-) cells; MPdG: ~24-fold compared to 
TP53(+/-) cells, ~13-fold compared to TP53(-/-) cells). 
 
Impact of TP53 status on the expression of DNA damage response proteins and SULTs in 
HCT116 cells treated with 1-HMP 
For Western blot analysis TP53(+/-), TP53(+/-), and TP53(-/-) cells were treated with 
10 M 1-HMP for 24 and 48 hours and whole cell lysates were analyzed for the expression of 
p53, p21 and SULT1A1/3. 1-HMP caused a strong induction of p53 and its downstream target 
p21 in TP53(+/+) cells (Figure 4). TP53(+/-) cells exhibited very low expression and no 
induction of p53 and p21 under these experimental conditions, whereas p53 was not detectable 
in TP53(-/-) cells. Basal SULT1A1/3 protein expression was much higher in TP53(+/+) cells 
than in TP53(-/-) and TP53(+/-) cells, which correlates with the significantly higher 1-HMP-
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 DNA adduct levels in the former. Treatment with 1-HMP had no impact on SULT1A1/3 
expression in any of the cell lines. 
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 DISCUSSION 
 
Previous studies in HCT116 cells have investigated the impact of p53 on the metabolic 
activation of several PAHs (e.g. BaP, dibenz[a,h]anthracene [DBA], dibenzo[a,l]pyrene 
[DBP]) and some nitroarenes (e.g. 3-NBA and aristolochic acid I) (Hockley et al. 2008; Simoes 
et al. 2008; Wohak et al. 2016; Wohak et al. 2018). A study of 3-NBA and its metabolites 3-
ABA and N-OH-3-ABA included investigations of SULTs, because the genotoxicity of 3-NBA 
is strongly enhanced by SULT1A1 and SULT1A2 (Arlt et al. 2017). Although treatment with 
3-NBA, 3-ABA, or N-OH-3-ABA had no effect on the induction of SULT1A1/3 proteins, 
results revealed a clear impact of TP53 status on basal expression of these enzymes (Wohak et 
al. 2018). To examine this phenomenon further 1-HMP was chosen in the present study as it is 
bioactivated mainly by SULTs (i.e. SULT1A1).  
 1-HMP-DNA adduct analysis in HCT116 cells revealed clearly the impact of TP53 
genotype on the SULT-mediated bioactivation of this compound, seen in higher MPdA and 
MPdG adduct levels in TP53(+/+) cells compared with TP53(+/-) and TP53(-/-) cells. MPdG 
levels were found to be ~20-fold higher than MPdA levels, in agreement with previous findings 
(Bendadani et al. 2014a; Bendadani et al. 2014b). The significantly higher adduct levels in 
TP53(+/+) cells could be explained by correspondingly higher SULT1A1/3 levels in this cell 
line, than in TP53(+/-) and TP53(-/-) cells.  
Bioactivation of 1-HMP in humans can be catalyzed by several SULTs, of which human 
SULT1A1 is reported to be by far the most efficient followed by 1E1. Furthermore SULT1A2, 
1A3, 1B1, 1C2, 1C3, 2A1, and 2E1 also convert 1-HMP into a genotoxic metabolite, but to 
much lower extents (Meinl et al. 2002; Meinl et al. 2013; Jiang et al. 2015). The antibody raised 
against SULT1A used in the present study detects SULT1A1 and 1A3 with a similar affinity. 
Both SULTs are prevalent in human colon (Dobbernack et al. 2011) although SULT1A1 
expression has been demonstrated to be ~2-fold lower than SULT1A3 (Teubner et al. 2007). 
In human intestinal carcinoma Caco-2 cells the difference is ~15-fold (Meinl et al. 2008). 
Besides SULT1A1 five other SULTs were found in these cells (SULT1A2, 1B1, 1C2, 2A1, 
1E1) with 1E1 being expressed only at very low levels. We can speculate that because 
SULT1A1 is much more efficient than SULT1A3 in activating 1-HMP (~110-fold) (Meinl et 
al. 2002; Meinl et al. 2013) the demonstrated impact of p53 on the bioactivation of 1-HMP in 
HCT116 cells is likely through SULT1A1 and not SULT1A3. In accordance with our study, 
Rothman and coworkers also found substantial higher basal SULT1A1 protein levels in 
HCT116 TP53(+/+) cells compared with TP53(-/-) cells, but they did not investigate SULT1A3 
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 (Rothman et al. 2015). Other SULTs in HCT116 cells have not been investigated, but should 
be considered when testing other carcinogens. The only other SULT detected in human colon 
that has been shown to bioactivate 1-HMP is SULT1B1 (Teubner et al. 2007).  
 An implication of the effect of p53 on SULT expression is that it could affect the 
toxicity of some dietary carcinogens and other environmental pollutants. A previous study has 
already indicated the tissue-dependent impact of p53 on the biotransformation of the food 
mutagen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) (Krais et al. 2016b). In 
addition to Cyp1a enzymes, Sult1a1 contributed to PhIP-DNA adduct formation in 
Trp53(+/+), Trp53(+/-), and Trp53(-/-) mice. Other examples that have yet to be studied are 
furfuryl alcohol and 5-hydroxymethylfurfural, rodent carcinogens that are activated to reactive 
intermediates by SULT1A1 (Sachse et al. 2014; Sachse et al. 2016). As mentioned, SULTs are 
also involved in the bioactivation of several environmental pollutants that carry nitro- or amino 
groups; for example, carcinogenic nitro- and aminotoluenes (Glatt et al. 2016). Used in large 
quantities for the synthesis of dyes, pesticides and synthetic rubbers, they may represent an 
occupational exposure hazard. Aminotoluenes also occur in tobacco smoke but the potential 
impact of p53 on their SULT-mediated biotransformation remains to be investigated.   
 In HCT116 cells, p53-mediated induction of CYP1A1 was observed after treatment 
with PAHs such as BaP, DBA and DBP (Wohak et al. 2016). When studying several 
chemotherapeutic drugs, it was found that etoposide and ellipticine induced CYP1A1 in 
HCT116 TP53(+/+) cells, but not in HCT116 TP53(-/-), demonstrating that the mechanism of 
CYP1A1 induction was p53-dependent, whereas cisplatin had no such effects (Willis et al. 
2018). In the present study, 1-HMP treatment did not result in the induction of SULT1A1/3. 
To date transcriptional regulation of SULTs is not well understood and a broad spectrum of 
transcription factors has been indicated to play a role in the regulation of these enzymes, e.g. 
PXR and CAR (Runge-Morris et al. 2013). Thus, further investigations are needed to clarify 
how p53 impacts on the basal expression of SULT1A in HCT116 cells.   
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 Conclusions 
 This study clearly links cellular TP53 status to the SULT1A1/3-mediated bioactivation 
of 1-HMP in vitro thereby broadening the spectrum of p53’s targets. This could be a critical 
determinant of genotoxicity as numerous environmental and dietary carcinogens are activated 
to chemically reactive metabolites via sulfation (O-sulfonation). As the underlying mechanism 
by which p53 function influences the expression of SULT1A1 remain elusive, we acknowledge 
that the effects observed in 1-HMF-treated HCT116 cells should be confirmed in other isogenic 
human cells that have been created using a different TP53 knockout strategy (e.g. 
CRISPR/Cas9 technology). Future investigations should include both in vitro and in vivo 
models to examine the impact of p53 on SULT-mediated bioactivation of 1-HMP. Since 
SULT1A1/3 plays a role in maintaining homeostasis of steroids and thyroid hormones these 
observations could also link p53 to other physiological pathways. Our results again highlight 
that gene-environment interactions need to be considered when studying carcinogen 
metabolism. 
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 FIGURE LEGENDS 
 
Figure 1: Bioactivation and DNA adduct formation of 1-hydroxymethylpyrene (1-HMP). 1-
HMP is converted by sulfotransferase 1A1 (SULT1A1) to the reactive intermediate 1-
sulfoxymethylpyrene (1-SMP) and the DNA adducts N6-(1-methylpyrenyl)-2’-
deoxyadenosine (MPdA) and N2-(1-methylpyrenyl)-2’-deoxyguanosine (MPdG). 
 
Figure 2: Effects of 1-HMP on cell viability in HCT116 TP53(+/+), TP53(+/-), and TP53(-/-
) cells treated with 1-HMP for 24 (A) and 48 hours (B). Values represent the mean ± SD (n=4); 
two separate incubations with two biological samples each. 
 
Figure 3: (A) 1-HMP-DNA adduct levels in HCT116 TP53(+/+), TP53(+/-), and TP53(-/-) 
cells treated with 10 µM 1-HMP for 24 hours. MPdA and MPdG adducts were quantified by 
LC-MS/MS. Values represent the mean ± SD (n=4); two separate incubations with two 
biological samples each. Statistical analysis was performed by one-way ANOVA followed by 
the Tukey post-hoc test (**p<0.01, ***p<0.005, different from HCT116 TP53(+/+) cells). 
Please note different scales in panels for MPdA and MPdG adducts. (B) UPLC-MS/MS 
chromatograms of digested DNA from HCT116 TP53(+/+) cells following incubation with 10 
µM 1-HMP for 24 hours. Results shown are representative of those obtained in 1-HMF-
exposed HCT116 TP53(+/-) and TP53(-/-) cells. Fragmentations of the analytes N6-MPdA, m/z 
= 466  350 (first panel), and N2-MPdG, m/z = 482  366 (third panel), were monitored 
together with the transitions of the internal standard substances [15N5]N
6-MPdA, m/z = 471  
355 (second panel), and [13C10,
15N5]N
2-MPdG, m/z = 497  376 (fourth panel). The ratio of 
the peak areas for the transition m/z = 466  350 (N6-MPdA) and for m/z = 471  355 
([15N5]N
6-MPdA) was used to calculate the N6-MPdA content of the DNA. Accordingly, the 
N2-MPdG was determined from the peak areas of m/z = 482  366 (N2-MPdG) and m/z = 497 
 376 ([13C10,15N5]N2-MPdG). 
 
Figure 4: Protein expression of p53, p21, and SULT1A1/3 in HCT116 TP53(+/+), TP53(+/-
), and TP53(-/-) cells treated with 10 µM 1-HMP for 24 and 48 hours. Blots shown are 
representative of experiments conducted at least twice and -actin was used as loading control. 
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